Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. The contributors focus on providing the rationale and background for translating the many promising biologically targeted therapies via clinical trials into effective new therapies. Among the interventional agents treated are: cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (Nf-kB and IL-8) for anti-angiogenesis therapies.
Indice testuale
Part I. Perspective on the Clinical Disease Management of Primary Malignant Melanoma Philip L. Bailin, Jon S. Meine, and Christine Poblete-Lopez A Pathologist's Perspective on Prognostic Features of Malignant Melanoma Ralph J. Tuthill Clinical Prognostic Factors and Staging Hamed Daw and Thomas Olencki Part II. Biological and Targeted Therapeutics Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression Peter A. Cohen, Suyu Shu, and James H. Finke Immunotherapy of Advanced Melanoma Directed at Specific Antigens Stanley P. L. Leong and Suyu Shu Melanoma Antigens: Vaccines and Monoclonal Antibodies Paul B. Chapman and Jedd D. Wolchok Interleukin-2 James W. Mier and Michael B. Atkins Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma Ronald M. Bukowski and Charles Tannenbaum Interferons: Preclinical and Clinical Studies in Melanoma Ernest C. Borden Biochemotherapy of Melanoma Lawrence E. Flaherty and Philip Agop Philip Signal Transduction Abnormalities as Therapeutic Targets Ruth Halaban and Maria C. von Willebrand Tumor Angiogenesis Bela Anand-Apte and Paul L. Fox Antiangiogenic Therapy for Melanoma Vann P. Parker
